Taken together, understanding the potential opposing roles of IL-1 agonists, such as IL-1α and IL-1β, during the initiation and progression of chronic intestinal inflammation, will shed further light on precise therapeutic modalities that will lead to more efficacious treatment of patients with IBD (Figure 3). This evidence concerns the gene IL1A and inflammatory bowel disease.